Although previous research was inevitably unable to identify subclinical inflammation, it is also clear that the occurrence of IBS-like symptoms in IBD patients is still higher than anticipated despite the use of sensitive biomarkers for inflammation, such as calprotectin and lactoferrin, which are supported by pan-endoscopy and biopsy to rule out ongoing inflammatory activity in its most subtle form [23]. This evidence concerns the gene LTF and irritable bowel syndrome.